Search
Oncolytics Biotech Inc
ONCYAdd to Watchlist
0.766USD
-0.004-0.52%
Close 09-21 16:00（ET）
95.60MMarket Cap
LossP/E TTM
More Details of Oncolytics Biotech Inc Company
Oncolytics Biotech Inc. is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype, turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. The Company is also advancing its programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/ HER2-) advanced and metastatic breast cancer (mBC) and metastatic pancreatic ductal adenocarcinoma (PDAC) to registration-enabled clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
Oncolytics Biotech Inc Profile
Ticker SymbolONCY
Company nameOncolytics Biotech Inc
IPO dateOct 05, 2001
CEOKelly (Jared Ryan)
Number of employees- -
Security typeOrdinary Share
Fiscal year-endOct 05
Address804, 322 - 11 Avenue Sw
CityCALGARY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryCanada
Postal codeT2R 0C5
Phone14036707377
Websitehttps://www.oncolyticsbiotech.com/
Ticker SymbolONCY
IPO dateOct 05, 2001
CEOKelly (Jared Ryan)
Company Executives of Oncolytics Biotech Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Allison Hagerman
Ms. Allison Hagerman
Vice President - Product Development
Vice President - Product Development
361.20K
+2.77%
Ms. Allison Hagerman
Ms. Allison Hagerman
Vice President - Product Development
Vice President - Product Development
361.20K
+2.77%
Ms. Allison Hagerman
Ms. Allison Hagerman
Vice President - Product Development
Vice President - Product Development
361.20K
+2.77%
Ms. Allison Hagerman
Ms. Allison Hagerman
Vice President - Product Development
Vice President - Product Development
361.20K
+2.77%
Mr. Kirk J. Look
Mr. Kirk J. Look
Chief Financial Officer
Chief Financial Officer
287.51K
-194.78%
Mr. Kirk J. Look
Mr. Kirk J. Look
Chief Financial Officer
Chief Financial Officer
287.51K
-194.78%
Mr. Kirk J. Look
Mr. Kirk J. Look
Chief Financial Officer
Chief Financial Officer
287.51K
-194.78%
Mr. Kirk J. Look
Mr. Kirk J. Look
Chief Financial Officer
Chief Financial Officer
287.51K
-194.78%
Ms. Amy G. Levin
Ms. Amy G. Levin
Vice President - Clinical Operations
Vice President - Clinical Operations
210.12K
+0.94%
Ms. Amy G. Levin
Ms. Amy G. Levin
Vice President - Clinical Operations
Vice President - Clinical Operations
210.12K
+0.94%
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Allison Hagerman
Ms. Allison Hagerman
Vice President - Product Development
Vice President - Product Development
361.20K
+2.77%
Ms. Allison Hagerman
Ms. Allison Hagerman
Vice President - Product Development
Vice President - Product Development
361.20K
+2.77%
Ms. Allison Hagerman
Ms. Allison Hagerman
Vice President - Product Development
Vice President - Product Development
361.20K
+2.77%
Ms. Allison Hagerman
Ms. Allison Hagerman
Vice President - Product Development
Vice President - Product Development
361.20K
+2.77%
Mr. Kirk J. Look
Mr. Kirk J. Look
Chief Financial Officer
Chief Financial Officer
287.51K
-194.78%
Mr. Kirk J. Look
Mr. Kirk J. Look
Chief Financial Officer
Chief Financial Officer
287.51K
-194.78%
FAQs
Who are the top five shareholders of Oncolytics Biotech Inc?
The top five shareholders of Oncolytics Biotech Inc are: Ms. Allison Hagerman
How many institutions hold shares of Oncolytics Biotech Inc (ONCY)?
As of 2025Q4, 96 institutions hold shares of Oncolytics Biotech Inc, with a combined market value of approximately 2.84M, accounting for 2.64% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -2963121.00.